U.S. Markets open in 8 hrs 3 mins

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) Investigation

NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eidos Therapeutics, Inc.

("Eidos" or the "Company") (EIDX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/eidx.

The investigation concerns whether Eidos and certain of its officers and/or directors have violated federal securities laws.

On April 1, 2019, after market-hours, Eidos filed Form 8-K with the SEC revealing that its previously issued financial statements for the first three quarterly periods in the year ended December 31, 2018 could no longer be relied upon.

If you are aware of any facts relating to this investigation, or purchased Eidos shares,you can assist this investigation by visiting the firm's site: www.bgandg.com/eidx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com: